狄诺塞麦骨质疏松症可以用吗？

The principle of (denosumab) is that it can inhibit osteoclasts, thereby reducing bone loss. Because the tumor cells in giant cell tumors of bone are very similar to osteoclasts, this drug has been borrowed into the treatment of giant cell tumors of bone. Today we will learn more about whether denosumab can be used for osteoporosis?

Osteoporosis is a bone disease that affects 40% of people with TDT (an inherited congenital blood disorder that results in reduced production of hemoglobin and red blood cells) and is one of the most prevalent comorbidities associated with the disease. People with osteoporosis have porous, brittle bones that break easily and often cause pain. Studies in multiple countries have demonstrated that denosumab (denosumab), a subcutaneous injection given every 6 months, can treat postmenopausal osteoporosis in women who are at increased risk of or at high risk of fracture (where applicable).

Denosumab (denosumab) treats osteoporosis by reducing bone formation and differentiation, increasing osteoclast apoptosis, and reversibly inhibiting bone resorption. Since denosumab will aggravate hypocalcemia, vitamin D deficiency must be corrected before starting treatment. It is recommended to fully supplement calcium and vitamin D during treatment. Patients with chronic kidney disease are effective in using denosumab without adjusting the dosage. Some patients with severely damaged renal function or patients receiving dialysis will develop severe hypocalcemia.

Compared with placebo, denosumab (denosumab) can increase the bone density of the lumbar spine and hip and reduce vertebral, non-vertebral and hip fractures. Compared with alendronate, denosumab treatment has better bone density than alendronate at all sites in patients who have not received or have received alendronate before, and it is relatively well tolerated. The most common side effects are skeletal muscle pain, hypercholesterolemia, and eczema.

Menopausal women with osteoporosis who are taking denosumab (denosumab) should not delay or interrupt denosumab treatment without subsequent anti-resorptive therapy (such as bisphosphonates, hormone therapy, or selective estrogen receptor modulators) or other treatment options to prevent rebound bone turnover markers or rapid bone mineral loss or increased risk of fractures.

The above is the introduction to the drug (denosumab), I hope it can help you!

Recommended related hot articles: /newsDetail/82256.html